KALA BIO, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 30, 2026, details the completion of the second closing of a private placement, the results of the Company's Annual Meeting of Stockholders, and a significant change in the composition of the Board of Directors. The reporting period covers events finalized on January 30, 2026, following an initial closing in November 2025.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company raised $4.2 million in gross proceeds from the sale of 2,100,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock at $2.00 per share.
- Total Private Placement: Combined with the first closing in November 2025 ($1.8 million), the total aggregate gross proceeds for the private placement reached $6.0 million.
- Dilution Potential: The Series AAA Preferred Stock is convertible into 420 shares of Common Stock per preferred share, representing an aggregate of 882,000,000 shares of Common Stock issuable upon conversion. The previously issued Series AA Preferred Stock is convertible into 49,500,000 shares of Common Stock.
- Authorized Shares: Stockholders approved an amendment to increase the number of authorized Common Stock shares to 1,500,000,000.
- Financial Performance: The filing does not provide specific revenue, profit, cash flow, or margin data for the period.
Material Changes Versus Prior Period
- Board Composition: Six incumbent directors (Marjan Farid, Andrew I. Koven, Mark Iwicki, Todd Bazemore, C. Daniel Meyers, and Howard B. Rosen) resigned effective immediately following the Annual Meeting. Their resignations were tied to the approval of the capital raise proposals and did not result from disagreements with the Company.
- New Director Appointments: Five nominees from AK Holdings Group Inc. were appointed to the Board: Avi Minkowitz, Hillel Posen, Chaim (Dovi) Berger, Yonatan Colman, and Brendan Purdy.
- Corporate Governance: New committee structures were established with the new directors, including Dovi Berger as Chair of the Audit Committee and Yonatan Colman as Chair of the Compensation Committee.
- Stock Structure: The Company authorized a reverse stock split of the Common Stock at a ratio between 1-for-2 and 1-for-100, to be implemented at the Board's discretion.
Outlook, Risks, and Management Commentary
- Investor Control: AK Holdings Group Inc. retains the right to nominate up to eight individuals to the Board of Directors pursuant to the November 2025 Purchase Agreement.
- Regulatory Compliance: The issuance of shares upon conversion of the preferred stock was approved by stockholders to comply with Nasdaq Listing Rules 5635(b) and 5635(d).
- Unregistered Sales: The sale of Series AAA Preferred Stock was exempt from registration under Rule 506(b) of Regulation D and/or Rule 903 of Regulation S. These shares are not registered and cannot be offered or sold in the U.S. absent registration or an applicable exemption.
- Future Actions: The Board has the discretion to determine the timing and specific ratio of the approved reverse stock split.
Key Facts for Investor Verification
- Verify the total potential dilution from the conversion of both Series AA (49.5M shares) and Series AAA (882M shares) preferred stock.
- Confirm the specific terms of the reverse stock split once the Board announces the ratio and effective date.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for covenants, liquidation preferences, and voting rights associated with the new preferred stock.
- Monitor the Company's cash burn rate and runway given the $6.0 million raised, as no operating revenue or profit figures were disclosed in this filing.
- Assess the impact of the new Board composition on strategic direction and corporate governance.